CEACAM5 and neoplasm: No statistically significant differences between the two groups were observed for liver function tests involving aspartate aminotransferase (25.6 ± 10.3 U/L vs. 25.5 ± 9.3 U/L, p = 0.92), alanine aminotransferase (31.4 ± 27.9 U/L vs. 29.1 ± 19.4 U/L, p = 0.39), and γ-glutamyl transpeptidase (22.0 ± 16.7 U/L vs. 24.5 ± 28.0 U/L, p = 0.46) measurements or for tumor markers including carcinoembryonic antigen (0.9 ± 0.6 ng/mL vs. 1.1 ± 0.7 ng/mL, p = 0.06) and carbohydrate antigen 19–9 (12.5 ± 14.9 U/mL vs. 13.0 ± 0.7 U/mL, p = 0.65).